RIPK3 and cholangiocarcinoma: To determine whether necroptosis is activated and contributes to the survival rates of CCA patients, phosphorylated MLKL (pMLKL) and RIPK1–RIPK3 interaction were developed to detect necroptosis activation in human primary tissues.